NovAccel, a Japanese company building a small superconducting accelerator to produce medical radioisotopes, said on 17 November 2026 that it had raised about ¥290m (about $1.9m) in what it called a post-seed extension round.
The shares were issued in a third-party allotment to XTech 3 Investment Limited Partnership, a fund managed by XTech Ventures, to Inoue Co. and to individual investors. No lead investor was named, and the company did not disclose a valuation or say how much the individual investors put in.
NovAccel said it would keep raising money. The funds will go to developing its RiSA accelerator and the process for making actinium-225 (Ac-225), to equipment and quality control for supplying samples, and to business development in Japan and abroad.
“このたび、XTech Ventures、株式会社イノウエ、そして個人投資家の皆様に、NovAccelの取り組みをご支援いただけることを大変心強く感じています。私たちが目指すのは、必要とされるAc-225を安定して供給できる仕組みをつくることです。”Ryo Yamashita, Representative Director, NovAccel
What NovAccel does
Ac-225 is a radioactive isotope that is expected to be effective in cancer treatment. NovAccel describes it as a key element for the next generation of targeted alpha therapy (TAT), a form of targeted radiation treatment, and its aim is to supply it from Japan to the rest of the world.
Its machine, RiSA (Radio-isotope production Superconducting Accelerator), is a compact superconducting electron accelerator designed only for making medical isotopes. The company said it does not chase the beam performance of general-purpose research accelerators. Instead it has prioritised small size and stable operation, with the goal of a machine that is cheap, uses little power and can be added to easily. It said 4K cooling and 2.6GHz cavity technology allowed it to shrink the design.
NovAccel is checking its production process with Japanese universities and research institutes. Through a US subsidiary, NovAccel Isotopes Inc., it is working on business development with drugmakers and research bodies outside Japan. The company said a supply business needs more than production technology: it also has to handle quality control, raw materials, transport and close work with customers.
Who invested
XTech Ventures invested through its third fund. In the release, the two XTech Ventures partners on the deal described NovAccel's team as being led by front-runners in Japanese superconducting accelerator research, joined by specialists in finance and pharmaceuticals.
Inoue Co. works in stainless steel and specialty metals. In the release, Inoue Co. said it would use its materials sourcing and its supply chains in Japan and abroad to help NovAccel reach mass production and stable supply.
NovAccel was founded in June 2024 and is based in Tsuchiura, Ibaraki Prefecture. It is led by representative director Ryo Yamashita. The company did not give a headcount or details of earlier funding. It has not said how much it has raised in total.
What the money is for
NovAccel set out three areas for the funds. The first is developing and testing RiSA and establishing the full Ac-225 production process, from irradiation to separation and purification.
The second is getting ready to send samples to drug companies and research institutes. That means buying equipment, setting up analysis and measurement methods and building a quality-control system.
The third is business development and preparation for volume production: closer work with customers and partners, arranging raw material supply and transport, and turning its plan for a mass-production site in Fukushima into concrete steps.
Independent news site Dellows News also reported the round, with the same amount, investors and planned uses of the money.
Company website: novaccel.jp
